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Abstract
Cardiovascular diseases (CVD) and type 2 diabetes (T2D) are closely interrelated complex
diseases likely sharing overlapping pathogenesis driven by aberrant activities in gene net-
works. However, the molecular circuitries underlying the pathogenic commonalities remain
poorly understood. We sought to identify the shared gene networks and their key intervening
drivers for both CVD and T2D by conducting a comprehensive integrative analysis driven by
five multi-ethnic genome-wide association studies (GWAS) for CVD and T2D, expression
quantitative trait loci (eQTLs), ENCODE, and tissue-specific gene network models (both co-
expression and graphical models) from CVD and T2D relevant tissues. We identified path-
ways regulating the metabolism of lipids, glucose, and branched-chain amino acids, along
with those governing oxidation, extracellular matrix, immune response, and neuronal sys-
tem as shared pathogenic processes for both diseases. Further, we uncovered 15 key driv-
ers including HMGCR, CAV1, IGF1 and PCOLCE, whose network neighbors collectively
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account for approximately 35% of known GWAS hits for CVD and 22% for T2D. Finally, we
cross-validated the regulatory role of the top key drivers using in vitro siRNA knockdown, in
vivo gene knockout, and two Hybrid Mouse Diversity Panels each comprised of >100
strains. Findings from this in-depth assessment of genetic and functional data from multiple
human cohorts provide strong support that common sets of tissue-specific molecular net-
works drive the pathogenesis of both CVD and T2D across ethnicities and help prioritize
new therapeutic avenues for both CVD and T2D.
Author summary
Cardiovascular disease (CVD) and type 2 diabetes (T2D) are two tightly interrelated dis-
eases that are leading epidemics and causes of deaths around the world. Elucidating the
mechanistic connections between the two diseases will offer critical insights for the devel-
opment of novel therapeutic avenues to target both simultaneously. Because of the chal-
lenging complexity of CVD and T2D, involving numerous risk factors, multiple tissues,
and multidimensional molecular alterations, few have attempted such an investigation.
We herein report a comprehensive and in-depth data-driven assessment of the shared
mechanisms between CVD and T2D by integrating genomics data from diverse human
populations including African Americans, Caucasian Americans, and Hispanic Ameri-
cans with tissue-specific functional genomics information. We identified shared pathways
and gene networks informed by CVD and T2D genetic risks across populations, confirm-
ing the importance of well-established processes, as well as unraveling previously under-
appreciated processes such as extracellular matrix, branched-chain amino acid metabo-
lism, and neuronal system for both diseases. Further incorporation of tissue-specific regu-
latory networks pinpointed potential key regulators that orchestrate the biological
processes shared between the two diseases, which were cross-validated using cell culture
and mouse models. This study suggests potential new therapeutic targets that warrant fur-
ther investigation for both CVD and T2D.
Introduction
Cardiovascular disease (CVD) and type 2 diabetes (T2D) are two leading causes of death in the
United States [1]. Patients with T2D are at two to six times higher risk of developing CVD com-
pared to those without T2D [2], indicating the importance of targeting common pathogenic
pathways to improve the prevention, diagnosis, and treatment for these two diseases. While
decades of work has revealed dyslipidemia, dysglycemia, inflammation, and hemodynamic dis-
turbances as common pathophysiological intermediates for both CVD and T2D [3–5], very few
studies have directly investigated the genomic architectures shared by the two diseases. While
genetic factors are known to play a fundamental role in the pathogenesis of both CVD and T2D
[6], a direct comparison of the top risk variants between these diseases has revealed few overlap-
ping loci in genome-wide association studies (GWAS) from multiple large consortia. Aside
from the speculation that the strongest genetic risks may be disease-specific, the agnostic
approach requiring the application of strict statistical adjustment for multiple comparisons also
increases false negative rate because of the lack of “genome-wide significance”.
To meet these challenges, we and others have previously shown that hidden disease mecha-
nisms can be unraveled through the assessment of the combined activities of genetic loci with
Shared gene networks and regulators for CVD and T2D
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weak to moderate effects on disease susceptibility by integrating GWAS with functional geno-
mics and regulatory gene networks [7–11]. Importantly, such high-level integration
approaches are able to overcome substantial heterogeneity between independent datasets and
extract robust biological signals across molecular layers, tissue types, and even species [8, 12–
14]. This advantage is mainly conferred by the aggregation of genetic signals from individual
studies onto a comparable ground–molecular pathways and gene networks, before conducting
meta-analysis across studies [14, 15]. In other words, even if the genetic variants and linkage
architecture can be different between studies, the biological processes implicated are more
reproducible and comparable across studies [16]. In the current investigation, we employed a
systematic data-driven approach that leveraged multi-dimensional omics datasets including
GWAS, tissue-specific expression quantitative trait loci (eQTLs), ENCODE, and tissue-specific
gene networks (Fig 1). GWAS datasets were from three well-characterized and high-quality
prospective cohorts of African Americans (AA), European Americans (EA), and Hispanic
Americans (HA)—the national Women’s Health Initiative (WHI) [8], the Framingham Heart
Study (FHS) [17], and the Jackson Heart Study (JHS) [18]. To maximize the reproducibility of
our findings across different populations, we also incorporated meta-analyses of CVD and
T2D genetics from CARDIoGRAMplusC4D [19] and DIAGRAM [20]. Further, we compre-
hensively curated functional genomics and gene networks derived from 25 tissue or cell types
relevant to CVD and T2D. A streamlined integration of these rich data sources using our Mer-
geomics pipeline [14, 15] enabled the identification of shared pathways, gene subnetworks,
and key regulators for both CVD and T2D across cohorts and ethnicities. Finally, we validated
the subnetworks using adipocyte and knockout mouse models, and confirmed their associa-
tions with cardiometabolic traits in the Hybrid Mouse Diversity Panel (HMDP) comprised of
>100 mouse strains [21–23].
Results
Identification of co-expression modules genetically associated with CVD
and T2D across cohorts
We first investigated whether genetic risk variants of CVD and T2D from GWAS of each
cohort/ethnicity were aggregated in a functionally coherent manner by integrating GWAS
with tissue-specific eQTLs or ENCODE information and gene co-expression networks that
define functional units of genes (Fig 1A). Briefly, co-expression networks were constructed
from an array of transcriptomic datasets of various tissues relevant to CVD and T2D (details
in Methods). These modules were mainly used to define sets of functionally related genes in a
data-driven manner. Genes within the co-expression modules (a module captures functionally
related genes) were mapped to single nucleotide polymorphisms (SNPs) that most likely regu-
late gene functions via tissue-specific eQTLs or ENCODE information. SNPs were filtered by
linkage disequilibrium (LD) and then a chi-square like statistic was used to assess whether a
co-expression module shows enrichment of potential functional disease SNPs compared to
random chance using the marker set enrichment analysis (MSEA) implemented in our Mer-
geomics pipeline (details in Methods) [14]. Subsequently, meta-analyses across individual
MSEA results at the co-expression module level were conducted using the Meta-MSEA func-
tion in Mergeomics to retrieve robust signals across studies. Among the 2,672 co-expression
modules tested, 131 were found to be significant as defined by false discovery rate (FDR) < 5%
in Meta-MSEA across studies (Table 1, S1 Table). Moreover, the majority of the disease rele-
vant tissues or cell types included in our analysis yielded informative signal, supporting the
systemic pathogenic perturbations known for CVD and T2D (S1 Fig). Of the significant mod-
ules identified, 79 were associated with CVD and 54 with T2D. Two modules were associated
Shared gene networks and regulators for CVD and T2D
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Fig 1. Framework of network-driven integrative genomics analyses. (A) Integration of genetics and functional genomics datasets to identify CVD and
T2D associated co-expression modules. The GWAS studies for CVD and T2D were derived from three independent cohorts representing three ethnic
populations: WHI (AA, EA, HA), FHS (EA), and JHS (AA). These independent datasets were supplemented with GWAS of coronary artery disease from
CARDIoGRAMplusC4D and T2D from DIAGRAM to increase power. We also curated a comprehensive list of tissue-specific functional genomics datasets,
including 2672 co-expression modules, human eQTLs of various tissues, and ENCODE based variants annotation. The significant modules were identified
by MSEA and Meta-MSEA, and then annotated to reveal shared pathways for CVD and T2D. In MSEA, the co-expression modules were used to define
data-driven gene sets each containing functionally related genes, tissue-specificity was determined based on the tissue-origins of the human eQTLs, and
ethnic specificity was determined based on the ethnicity of each GWAS cohort. (B) Identification of disease key drivers and subnetworks. We utilized multi-
tissue graphical networks to capture key drivers for disease associated co-expression modules using wKDA, then prioritized KDs based on consistency and
disease relevance of the subnetworks. (C) Validation of the top key drivers and their subnetworks via intersection with known human CVD and T2D genes
from DisGeNET and GWAS catalog, in vitro adipocyte siRNA experiments, and cross-validation at both transcriptomic and genomic levels in the hybrid
mouse diversity panels (HMDP).
https://doi.org/10.1371/journal.pgen.1007040.g001
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with both diseases, with one enriched for “carbohydrate metabolism” genes and the other
over-represented with “other glycan degradation; known T2D genes” (Fig 2A, S1 Table).
Examination of these two shared modules showed that the genetic signals driving the module
significance were largely different between CVD and T2D, with 14.8% lead SNPs overlapping
for the carbohydrate metabolism module and 5.8% lead SNPs overlapping for the glycan deg-
radation module between diseases. These results indicate that the GWAS signals for the two
diseases in each module do not necessarily overlap, but the CVD and T2D genes are likely
functionally connected since they are co-expressed in the same modules and annotated with
coherent functions. Additionally, the majority of the CVD modules and T2D modules were
identified in more than one ethnic group based on MSEA analysis of individual studies, sup-
porting consistency across ethnicities (Fig 2B).
Table 1. Summary of top co-expression modules associated with CVD or T2D (FDR < 1% in Meta-MSEA, in column FDRmeta).
Disease Module ID Tissue Annotation Gene No. CAR+C4D/ DIAGRAM JHS FHS WHI WHI WHI Pmeta FDRmeta
Mixed AA EA EA AA HA
CVD 4406 O1, O2, O5 NA 154 3.32E-10 NS - 2.83E-02 4.41E-03 NS 5.73E-09 <0.01%
4522 Adp, Lv, T Signaling by FGFR mutants 2072 1.03E-04 1.62E-02 - 3.80E-02 5.53E-03 2.86E-02 3.39E-08 <0.01%
4540 O4, O5 NA 1233 9.72E-04 NS - NS 1.50E-02 5.52E-04 5.07E-07 0.06%
5242 Adr Cholesterol Biosynthesis 306 4.19E-06 4.71E-02 - NS 2.31E-02 NS 2.64E-06 0.08%
4087 Adp, Dg Carboxylic acid metabolic process 158 2.34E-06 NS - NS 8.63E-03 2.17E-02 4.24E-06 0.09%
4019 Ly Transmembrane transport of small molecules 2876 1.89E-03 4.46E-02 - NS NS 6.85E-04 7.91E-06 0.20%
4941 O4, O5 Establishment of localization 908 8.97E-06 1.52E-02 - NS NS 3.94E-02 2.72E-06 0.21%
5023 Ly TCA cycle and respiratory electron transport 2890 NS 6.37E-05 - 1.53E-03 NS 1.50E-02 1.15E-05 0.22%
blue O2, O4 Cell cycle 657 1.08E-02 NS - NS NS 1.77E-04 3.85E-06 0.30%
5329 Adr Biological oxidations 1028 NS 2.32E-02 - 5.01E-03 3.26E-02 2.26E-02 2.21E-05 0.35%
124 O3, O4 NA 14 NS 1.48E-03 - NS 7.05E-07 NS 4.86E-06 0.55%
4656 O3, O4 Cellular protein complex assembly 371 NS NS - NS 3.64E-03 2.27E-04 8.85E-06 0.67%
4147 O5 NA 111 1.55E-02 2.06E-04 - NS 8.85E-03 NS 5.72E-06 0.68%
4989 Adr Metabolism of amino acids and derivatives 453 1.86E-03 7.41E-03 - NS 3.71E-04 NS 7.81E-05 0.82%
T2D 5323 Mn NA 38 8.68E-04 NS NS 2.25E-04 1.05E-03 NS 1.58E-07 0.02%
5250 Adp, Dg, Mn NA 37 4.78E-05 NS NS 3.01E-02 3.46E-07 NS 4.32E-07 0.03%
4880 Mn NA 141 8.96E-03 NS 1.18E-02 5.06E-04 NS NS 1.61E-06 0.06%
6872 Mn NA 119 NS 1.26E-03 7.44E-03 7.79E-03 NS NS 1.26E-06 0.06%
4879 Ms NA 376 3.18E-02 NS 5.88E-04 NS 2.66E-03 2.20E-03 1.19E-06 0.14%
6533 Mn Cholesterol biosynthesis 48 NS 5.02E-03 NS NS NS 1.26E-06 1.06E-05 0.25%
6977 Bld, O3 NA 40 3.66E-02 NS 4.01E-05 NS 1.81E-02 4.05E-02 1.71E-06 0.39%
6675 Mn Cholesterol biosynthesis 152 3.72E-03 3.35E-02 NS NS NS 2.06E-05 2.56E-05 0.52%
37 O2 NA 34 1.94E-03 5.53E-03 NS NS 9.38E-04 NS 4.95E-06 0.57%
4302 Adp NA 40 2.07E-03 NS NS 4.80E-03 4.05E-06 NS 9.89E-06 0.71%
6690 Adr Complement and coagulation cascades 641 1.93E-02 1.01E-04 NS 2.24E-02 NS NS 1.36E-05 0.86%
4059 Dg SLC mediated transmembrane transport 51 NS 3.05E-02 5.80E-03 NS 1.50E-02 NS 1.29E-05 0.86%
4937 Dg Amino acid metabolic process 80 9.21E-03 NS 5.88E-03 NS 1.37E-03 NS 2.11E-05 0.89%
5059 Ve TCA cycle and respiratory electron transport 164 7.31E-04 NS 2.74E-02 8.66E-04 NS NS 6.64E-06 0.95%
Module IDs were randomly assigned IDs to co-expression modules. The annotation refers to the top functional category enriched in the co-expression
modules (Bonferroni-corrected p< 0.05 based on Fisher’s exact test, number of direct overlapping genes > 5). Numbers in scientific format were p-values
from MSEA or Meta-MSEA analysis, and those reaching FDR < 20% in individual cohort analysis via MSEA (not the FDRmeta in Meta-MSEA) are
highlighted in bold. CAR+C4D: CARDIoGRAMplusC4D; Mixed: mixed ethnicities; JHS: Jackson Heart Study; FHS: Framingham Heart Study; WHI:
Women’s Health Initiative; AA: African Americans; HA: Hispanic Americans; EA: European Americans; Pmeta and FDRmeta: p and FDR values from Meta-
MSEA analysis across cohorts. Adp–adipose tissue; Adr—adrenal gland; Bld–Blood; Dg—digestive tract; Lv–liver; Ly–lymphocyte; Mn-monocyte; Ms–
muscle; O1 –chromosomal distance mapping based on a 50kb window; O2 –ENCODE-based Regulome SNPs; O3 –combining all tissue-specific eQTLs
into a single multi-tissue eSNP set; O4 –merging eQTL sets with Regulome data; O5 –combined mapping (distance, eQTLs, ENCODE); T–thyroid gland;
Ve–vascular endothelium.
https://doi.org/10.1371/journal.pgen.1007040.t001
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Shared biological processes among the CVD/T2D-associated co-
expression modules
Apart from the two directly overlapping modules, between the CVD- and T2D-associated
modules there were many overlapping genes, indicating additional shared functions that con-
tribute to both diseases (S2 Fig). Upon annotating the disease-associated modules using func-
tional categories curated in Kyoto Encyclopedia of Genes and Genomes (KEGG) and
Reactome while correcting for the overlaps between pathways (method details in S1 Text; S3
Fig; S2 Table), we found significant functional overlaps between the CVD and T2D modules
(overlap p = 3.1e-15 by Fisher’s exact test, Fig 2C). We further ranked all the enriched func-
tional categories by the number of CVD/T2D modules that were annotated with each func-
tional term (Fig 3), which showed a wide spectrum of biological processes shared by both
CVD and T2D across ethnicities and cohorts. Of the top ranked processes for the significant
co-expression modules identified, we observed well-established pathogenic processes such as
lipid and fatty acid metabolism [24], glucose metabolism [25], oxidation [26], and cytokine sig-
naling [27]. Pathways previously implicated mainly for T2D such as beta-cell function were
also found to be shared for both CVD and T2D. Interestingly, our completely data-driven
approach also identified extracellular matrix (ECM) and branched chain amino acids (BCAA)
metabolism as top functional categories whose roles in the development of cardiometabolic
disorders have only been implicated in recent experimental work [28–30]. Furthermore, our
Fig 2. Venn diagrams of overlap in significant co-expression modules and functional categories
between diseases and ethnicities. A) Count of module overlaps by disease based on Meta-MSEA; B)
Count of module overlaps for each disease by ethnicity based on MSEA of individual studies. Co-expression
modules captured in CARDIoGRAMplusC4D and DIAGRAM were not counted due to uncertain ethnic origin;
C) Count of independent functional category overlaps by disease based on results from Meta-MSEA in panel
A.
https://doi.org/10.1371/journal.pgen.1007040.g002
Shared gene networks and regulators for CVD and T2D
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analysis also revealed under-appreciated processes involving the neuronal system and trans-
port of small molecules.
Fig 3. Summary of 41 independent functional categories enriched in both CVD and T2D co-expression modules (Bonferroni-corrected p< 0.05
based on Fisher’s exact test, number of direct overlapping genes > 5). Independent functional categories were defined as the categories with pair-wise
overlapping ratio < 10%. Red and blue block indicates that the significant CVD or T2D co-expression modules identified from the study and ethnicity origin are
enriched for the particular functional category term. CAR+C4D: CARDIoGRAMplusC4D; M: mixed ethnicities; AA: African Americans; HA: Hispanic
Americans; EA: European Americans.
https://doi.org/10.1371/journal.pgen.1007040.g003
Shared gene networks and regulators for CVD and T2D
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1007040 September 28, 2017 7 / 25
Identification and prioritization of key drivers (KDs) and subnetworks for
the CVD/T2D-associated modules
The coexpression networks used above mainly served to capture coexpression patterns
between genes and to define data-driven gene sets that contain functionally related genes, but
they do not carry detailed topology information on gene-gene regulatory relationships. To dis-
sect the gene-gene interactions within and between the 131 disease-associated modules, and to
identify key perturbation points shared for both CVD and T2D modules, we used the GIANT
networks [31] and Bayesian networks (BNs) from 25 CVD and T2D relevant tissue and cell
types, which provide detailed topological information on gene-gene regulatory relationships
necessary for the downstream network analysis. The BNs used in our study were generated
using similar sets of mouse and human gene expression datasets as used for the co-expression
networks, but additionally incorporated genetic data to model causal gene regulatory net-
works, whereas the GIANT networks were derived based on independent gene expression
datasets and protein interaction information. We included both types of gene regulatory net-
works to increase the coverage of functional connections between genes and only considered
KDs identified in both to enhance the robustness of KD prediction.
Specifically, all genes in each of the co-expression modules genetically associated with
CVD or T2D as identified in our study were mapped onto the GIANT and BN graphical
networks to identify KDs using the weighted key driver analysis (wKDA) implemented in
Mergeomics [14], where KDs were defined as genes whose local network neighborhoods
demonstrate significant enrichment of genes from disease-associated modules (details in
Methods; concept depicted in S4 Fig). Of note, wKDA gives higher weight to network
edges that are consistent across network models constructed from independent studies,
therefore alleviating potential bias caused by dataset heterogeneity. We identified 226 KDs
that were consistently captured in Bayesian and GIANT network at Bonferroni-corrected p-
value < 0.05 (Fig 1B), among which 162 were KDs for both CVD and T2D associated mod-
ules. Bonferroni-correction was used here to focus on the strongest KDs for prioritization
purposes. To further prioritize these 162 shared KDs, tissue-specific subnetworks of these
KDs were evaluated using Meta-MSEA to rank the magnitude of their genetic association
with CVD and T2D across cohorts, yielding 15 top-ranked KDs at FDR<10% in Meta-
MSEA for CVD and T2D separately (combined FDR<1% for both diseases simultaneously)
(Fig 1B, Table 2). The top KD subnetworks were related to similar pathogenic processes
highlighted in the previous section, including cholesterol biosynthesis, respiratory electron
transport, immune system and ECM. We further inferred the directionality of the effects of
each specific KD on both diseases using GWAS signals mapped to each KD based on eQTLs
or chromosomal distance (details in Methods; results in S5 Fig). This analysis differentiated
the KDs into those showing consistent direction of association for both CVD and T2D
(ACLY, CAV1, SPARC, COL6A2, IGF1), inverse directions with CVD and T2D (HMGCR,
IDI1), and uncertain directions (Table 2). Therefore, the shared KDs do not necessarily
affect the risks for the two diseases in the same direction.
Shared KDs and subnetworks orchestrate known CVD and T2D genes
The KDs and subnetworks were identified based on the full spectrum of genetic evidence
(from strong to moderate and subtle) from the various GWAS datasets examined in the cur-
rent study. To assess whether the top KD subnetworks were enriched for previously known
disease genes that mostly represent the strong and replicated genes as a means of cross-valida-
tion, we manually curated previously reported genes associated with CVD, T2D, and interme-
diate metabolic traits related to CVD, T2D (glucose, insulin, lipids, obesity) from DisGeNET
Shared gene networks and regulators for CVD and T2D
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[32] and the NHGRI GWAS Catalog [6] (Fig 1C, genes listed in S3 Table). The connection
between the top 15 KDs and known genes for CVD, T2D and relevant cardiometabolic traits
was confirmed by the significant over-representation of the known disease genes in KD sub-
networks, with fold enrichment as large as 8, confirming the strong biological importance of
these KDs (Fig 4A). Further, the top 15 KDs showed direct connections to 28 GWAS hits
Table 2. Summary of the 15 key drivers and their corresponding subnetworks shared by CVD and T2D.
Key
drivers
Gene name Sub-
net
size
Tissues PCVD FDRCVD PT2D FDRT2D No. of
CVD
module
No. of T2D
module
Suggestive genetic
effect direction
(CVD/T2D)
Subnetwork
function
ACAT2 Acetyl-CoA
Acetyltransferase 2
192 Adp, Dg, Lv,
Ms, T
1.24E-03 5.32% 5.37E-03 4.35% 6 7 uncertain Cell cycle;
Cholesterol
biosynthesis
ACLY ATP Citrate Lyase 129 Adp, Dg, Lv,
Ms
5.96E-04 6.17% 5.78E-05 0.47% 5 6 consistent Cholesterol
biosynthesis;
Steroid biosynthesis
CAV1 Caveolin 1 954 Adp, Adr,
Art, Dg, Ms,
T, Ve
1.24E-05 0.20% 3.96E-05 0.32% 7 4 consistent Immune system;
Focal adhesion
COL6A2 Collagen Type VI Alpha
2 Chain
294 Adp, Adr,
Dg, Ms, T
2.47E-03 4.45% 4.97E-05 0.40% 2 1 consistent Extracellular matrix
COX7A2 Cytochrome C Oxidase
Subunit 7A2
152 Adp, Adr,
Art, Bld, Dg,
Lv, Ly
2.34E-04 3.79% 1.31E-04 1.85% 1 4 uncertain Respiratory electron
transport
DBI Diazepam Binding
Inhibitor
181 Adp, Art, Bld,
Dg, Is, Lv,
Ly, Ms
1.57E-03 7.70% 1.33E-02 6.75% 5 5 uncertain Respiratory electron
transport
HMGCR 3-Hydroxy-
3-Methylglutaryl-CoA
Reductase
75 Art, Dg, Lv,
Ms
7.53E-03 9.09% 7.28E-03 4.87% 1 5 opposite Cholesterol
biosynthesis;
Steroid biosynthesis
IDI1 isopentenyl-
diphosphate delta
isomerase 1
89 Adp, Art, Dg,
Is, Lv, Ms, T
6.77E-03 8.95% 2.13E-03 3.46% 3 4 opposite Cholesterol
biosynthesis;
Steroid biosynthesis
IGF1 insulin like growth
factor 1
993 Adr, Ms 2.65E-03 5.37% 3.71E-04 1.20% 7 2 consistent Immune system;
Focal adhesion
MCAM melanoma cell
adhesion molecule
183 Adp, Adr,
Art, Ms, T
2.65E-03 7.16% 1.93E-03 5.22% 4 2 uncertain Extracellular matrix
MEST mesoderm specific
transcript
132 Adp, Adr, Lv,
Ms
1.66E-03 3.36% 6.84E-04 1.58% 4 2 uncertain Fibroblast growth
factor signaling
MSMO1 methylsterol
monooxygenase 1
133 Adp, Art, Dg,
Lv, Ms, T,
2.38E-03 7.70% 4.34E-05 0.63% 1 4 uncertain Cholesterol
biosynthesis;
Steroid biosynthesis
PCOLCE procollagen C-
endopeptidase
enhancer
307 Adp, Adr,
Art, Hy, Lv,
Ms
1.14E-03 6.17% 1.71E-06 0.03% 2 2 uncertain Extracellular matrix
SPARC secreted protein acidic
and cysteine rich
482 Adp, Adr,
Art, Dg, Lv,
Ms, Ve
1.81E-03 9.63% 2.02E-03 8.18% 5 3 consistent Extracellular matrix
ZFP36 ZFP36 ring finger
protein
176 Adp, Adr,
Art, Lv, Ly,
Ms
1.42E-03 8.45% 1.64E-02 7.69% 3 3 uncertain Hypoxia-inducible
factors; CD40
signaling
P and FDR values were based on Meta-MSEA analysis of the KD subnetworks for enrichment of CVD or T2D GWAS signals across cohorts. The
subnetwork size indicates the number of neighboring genes directly connected to a KD when all the tissue-specific networks where the KD was found are
combined. No. of module columns indicate the number of CVD or T2D–associated co-expression modules from which each KD was identified. Suggestive
genetic effect direction was designated “consistent” or “opposite” if the proportion of variants having consistent or opposite effect direction in CVD or T2D
was statistically significant in either eQTL mapping or chromosomal distance mapping. Otherwise, “uncertain” was called. Subnetwork function was
annotated based on KEGG and Reactome databases. Adp–adipose tissue; Adr—adrenal gland; Art–artery; Dg—digestive tract; Is–Islet; Hy–
hypothalamus; Lv–liver; Ly–lymphocyte; Ms–muscle; T: thyroid gland; Ve: vascular endothelium.
https://doi.org/10.1371/journal.pgen.1007040.t002
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reaching genome-wide significance (p< 5e-8) for CVD and 16 for T2D, which account for
35% (fold = 3.35, p = 7.18e-10) and 22% (fold = 2.16, p = 8.08e-4) of all reported significant
GWAS signals for CVD and T2D in GWAS catalog, respectively. Two of the 15 top KDs,
namely HMGCR and IGF1, were previously identified as signals of genome-wide significance
for obesity, lipids and T2D, all risk factors of CVD. Additionally, network visualization
revealed tissue-specific KDs and interactions of CVD and T2D genes in many disease-relevant
tissues including adipose, adrenal gland, artery, blood, digestive tract (small intestine, colon),
hypothalamus, islet, liver, lymphocyte, skeletal muscle, thyroid, and vascular endothelium (Fig
4B). PCOLCE represents an intriguing hypothalamus KD that interacts with important energy
homeostasis genes like leptin receptor LEPR, suggesting a role of neurohormonal control in
CVD and T2D pathogenesis. In contrast, CAV1 appeared to interact extensively with other
KDs in peripheral tissues, especially in the adipose tissue.
Fig 4. Subnetworks of the top 15 shared KDs orchestrate known genes for CVD, T2D, obesity and lipids. A) Fold enrichment of KD subnetwork genes
for known genes related to cardiometabolic traits reported in DisGeNET. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. B) Top KD subnetworks with
GWAS hits (p < 1e-5 as reported in GWAS Catalog) for cardiometabolic traits. KDs are large nodes. Edge color denotes tissue-origin. Only high-confidence
edges (those with weight score in the top 20%) are visualized.
https://doi.org/10.1371/journal.pgen.1007040.g004
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Experimental validation of CAV1 subnetworks using an in vitro adipocyte
model and in vivo knockout mouse model
CAV1 is a robust KD for CVD- and T2D-associated modules across multiple tissues, with the
adipose tissue subnetwork of CAV1 containing the largest number of neighboring genes (Fig
4B). In addition, adipose tissue is the only tissue where CAV1 is a KD in both the Bayesian net-
works and GIANT networks. These lines of evidence implicate the potential importance of
CAV1 adipose subnetwork in the shared pathogenesis for both diseases. Indeed, Cav1-/- mice
have been shown to alter the lipid profile, susceptibility to atherosclerosis, and insulin resis-
tance [33, 34]. To assess whether perturbation of this potential KD induces changes in the sub-
network genes as predicted by our network modeling, we performed validation by conducting
siRNA-mediated knock down of Cav1 in differentiating mouse 3T3-L1 adipocytes and by eval-
uating the whole transcriptome alteration in mouse gonadal adipose tissue between wild type
and Cav1-/- mice [33] (Fig 1C; details in Methods). Of the 12 adipose network neighbors of
Cav1 that were tested in vitro, 6 exhibited significant changes in expression level on day 2 after
~60% Cav1 knockdown using two siRNAs against Cav1. In contrast, none of the 5 negative
controls, which were randomly selected among adipocyte genes that are not connected to
Cav1 or its first level neighbors in the adipose network, were affected after Cav1 perturbation
(Fig 5A). Cav1 knockdown also led to decreased expression of Pparg, a major adipocyte differ-
entiation regulator (S6 Fig), supporting a role of Cav1 in adipocyte differentiation as previ-
ously observed [35].
In 3-month-old Cav1-/- mice which showed perturbed lipid and insulin sensitivity profiles,
we observed 1,474 differentially expressed genes (DEGs) at FDR<1%. We found that the first
and second level neighbors of CAV1 in our predicted subnetwork showed significant enrich-
ment for DEGs in adipose tissue induced by Cav1 knockout, with the degree of fold enrich-
ment increasing as the statistical cutoff used to define DEGs became more stringent (Fig 5B;
subnetwork view with DEGs in S7 Fig). On the contrary, the third and fourth level neighbors
of CAV1 in our predicted subnetwork did not exhibit such enrichment of DEGs (Fig 5B).
These experimental findings support that CAV1 is a key regulator of the subnetwork and the
network structure predicted by our network modeling is reliable, although it is difficult to dis-
cern whether the network changes are related to alterations in adipocyte differentiation status.
We also observed strong enrichment for the focal adhesion pathway in both the predicted
Cav1 adipose subnetwork (p = 9.6e-14 by Fisher’s exact test, fold enrichment = 6.0) and the
differential adipose genes in Cav1-/- mice (p = 6.9e-9, fold enrichment = 3.5).
Shared KDs are associated with CVD and T2D traits in experimental
mouse models
We further assessed the transcriptomic profiling in adipose (relevant to T2D and CVD) and
aorta tissue (main site of CVD) in relation to 7 cardiometabolic phenotypes including adi-
posity, lipid levels (triglyceride, LDL, HDL), fasting glucose, fasting insulin and HOMA-IR,
across >100 mouse strains in two HMDP panels [21–23]. HMDP is a systems genetics
resource that comprises more than 100 commercially available mouse strains differing in
genetic composition, and has emerged as a power tool to study complex human diseases [22,
36]. The biological relevance of HMDP to human pathophysiology has been reproducibly
demonstrated [37–39]. Moreover, HMDP data was completely independent of the human-
focused genetic datasets and the network datasets used in our primary integrative analysis (Fig
1C). Here we selected two specific HMDP panels, high-fat (HF) and atherogenic (ATH), in
which mice were either fed with a high-fat high-sucrose diet or underwent transgenic expres-
sion of human APOE-Leiden and CETP gene as a pro-atherogenic background, respectively.
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These two panels were chosen for their representativeness of human T2D (the HF panel) and
CVD (the ATH panel) pathology. First, we investigated the correlation between the expression
of 14 top KDs (no probe for KD MSMO1 in HMDP) and cardiometabolic traits in the adipose
and aorta tissues assessed in HMDP. All 14 KDs displayed significant trait association in
HMDP, with the association for 11 KDs replicated in both the HF and ATH HMDP panels
(Fig 6A). Next, we retrieved the adipose and aorta gene-trait correlation statistics for the top
KD subnetwork genes, and used MSEA to test whether genes in the KD subnetworks displayed
an overall overrepresentation of strong trait association in HMDP. Again, the 14 KD subnet-
works showed significant trait association after Bonferroni correction (Fig 6B). These findings
support that the close involvement of the KDs in cardiometabolic trait perturbation we pre-
dicted based on human datasets can be cross-validated in mouse models.
Fig 5. Validation of CAV1 subnetwork using in vitro siRNA knockdown (A) and in vivo knockout mouse model
(B). A) Fold change of expression level for CAV1 subnetwork and negative control genes 2 days after Cav1
knockdown using two siRNAs separately. Twelve CAV1 neighbors were randomly selected from the first and
second level neighboring genes of CAV1 in adipose network. Five negative controls were randomly selected
from the genes not connected to CAV1 or its first level networks in adipose network. Statistical significance of
genes was determined by linear model, adjusting for batch effect and siRNA differences. N = 6/siRNA group,
mean ± SEM, *p < 0.05, **p < 0.01, ***p<0.001. B) Overlap of CAV1 neighboring genes in the adipose tissue
subnetwork at various distance levels with the differentially expressed genes in the gonadal adipose tissue in
Cav1 knockout mice (N = 3/group). Overlap p-value is determined by Fisher’s exact test. *Overlap p < 0.05 after
Bonferroni correction.
https://doi.org/10.1371/journal.pgen.1007040.g005
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Causal implication of the shared KD subnetworks in experimental mouse
models
Cav1 knockout in mice led to dysreuglation of the predicted subnetwork (Fig 5B) and signifi-
cant alterations in cardiometabolic phenotypes [33, 34], supporting the causal role of CAV1 in
both CVD and T2D. To further investigate the potential causal role of the top KDs and their
subnetworks in CVD and T2D, we conducted integrative analysis of the KD subnetworks to
assess their disease association using GWAS results for the 7 cardiometabolic traits from
HMDP and tissue-specific cis-eQTLs (Fig 1C). By mapping GWAS signals to genes using adi-
pose or aorta eQTLs and testing for enrichment of genetic association with cardiometabolic
traits within the KD subnetwork genes using MSEA, we found consistent and significant asso-
ciation between cardiometabolic traits and the subnetworks of KDs ACAT2, CAV1, COL6A2,
IGF1, PCOLCE, and SPARC across adipose and aorta (Fig 6C). These results informed by
mouse GWAS support a potential causal role of these top KDs in perturbing gene networks in
multiple tissues to trigger CVD and T2D.
Fig 6. Associations of KDs and subnetworks with cardiometabolic traits in mice. (A) Association between KD expression and cardiometabolic traits in
adipose tissue from HF-HMDP (HF) and aorta tissue from atherogenic-HMDP (ATH) as determined by Pearson correlation. *p< 0.05; **p< 0.05 after
Bonferroni correction for the KD number; ***p< 0.05 after Bonferroni correction for the number of KDs and traits. (B) Transcriptomic-wide association of KD
subnetworks and cardiometabolic traits in adipose tissue from HF-HMDP, and aorta tissue from atherogenic-HMDP, as evaluated by MSEA. (C) Genome-
wide genetic association of KD subnetworks and cardiometabolic traits based on adipose eQTL mapping in HF-HMDP, and aorta eQTL mapping in
Atherogenic-HMDP, as determined by MSEA. p<0.05, p<3.3–3, and p<4.8e-4 correspond to uncorrected and Bonferroni-corrected p-values (correcting for
the number of KDs or for the number of KD and trait combinations).
https://doi.org/10.1371/journal.pgen.1007040.g006
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Discussion
CVD and T2D are highly correlated complex diseases and share many common risk factors.
Multiple genetic variants may individually exert subtle to strong effects on disease pathogene-
sis, and in aggregate perturb diverse pathogenic pathways [8, 9, 13, 19, 20, 40]. In this systems-
level, data-driven analysis of GWAS from several large and high-quality cohorts of diverse eth-
nicities, integrated with functional data (from ENCODE, eQTLs, tissue-specific co-expression
and regulatory networks constructed from human and mouse experiments), we identified
both known and novel pathways and gene subnetworks that were genetically linked to both
CVD and T2D across cohorts and ethnicities. Further, KDs in tissue-specific subnetworks
appear to regulate many known disease genes for increased risk of CVD and T2D. Lastly, we
experimentally validated the network topology using in vitro adipocyte and data from in vivo
gene knockout models, and confirmed the role of the top KDs and subnetworks in both CVD
and T2D traits in independent sets of mouse studies.
The data-driven nature of the current study offers several strengths. First, we incorporated
the full-scale of genetic variant-disease association from multiple cohorts, ethnicities and dis-
ease endpoints, allowing for the detection of subtle to moderate signals, as well as comparison
and replication of results across diseases and populations. More importantly, by focusing on
results that demonstrate consistent significance at pathway and network level, we overcome
the difficulties in harmonizing independent datasets that are complicated by substantial het-
erogeneity due to platform differences and population substructure. This is because disease
signals across populations are more conserved at pathway level than at individual variant and
gene levels [12, 14, 16]. Second, the comprehensive incorporation of tissue-specific eQTLs,
coupled with the use of tissue-specific networks, enhances our ability to achieve better func-
tional mapping between genetic variants and genes, and uncover systems-level regulatory cir-
cuits for CVD and T2D in a tissue-specific fashion. Third, data-driven modules and networks
used in this study increase the potential for novel discovery as gene-gene interactions are
defined by data rather than prior knowledge. As the network models were from many inde-
pendent studies reflecting diverse physiological conditions, leveraging these datasets and net-
work models offers more comprehensive coverage of biological interactions than any given
dataset can provide and has proven a valuable approach to unveil novel biological insights [9,
13, 41]. While some of our findings confirmed those from previous canonical pathway-based
analysis on disease processes including ECM-receptor interaction and cell-adhesion, and KDs
such as SPARC [8], our data-driven approach in the current study uncovered numerous novel
genes, pathways, and gene subnetworks. A likely reason for the enhanced discovery potential
of co-expression modules is that several interacting pathways could be co-regulated in a single
module, or a pathway could interact with other poorly annotated processes in a module to
together confer disease risk. The use of modules capturing such interactions improves the sta-
tistical power, in contrast to testing the pathways individually. Lastly, we conducted cross-vali-
dation studies in support of the functional roles of specific KDs and subnetworks in CVD and
T2D using independent experimental models.
We acknowledge the following limitations in our study. First, our analyses were constrained
by the coverage of functional datasets that are currently available, which causes uneven tissue
coverage between data types and statistical bias towards more commonly profiled tissues such
as adipose and liver, making it difficult to achieve precise inference for all relevant tissues.
Although we believe this does not necessarily undermine the validity of the main findings from
our study, we acknowledge that we likely have missed relevant biology from tissues with fewer
studies and smaller sample sizes. Further investigation is needed when additional relevant data-
sets become available. Secondly, our FDR estimates in MSEA do not take into consideration the
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gene overlap structure among co-expression modules, due to the challenge in accurately adjust-
ing for the various degrees of overlaps between module pairs. To alleviate this limitation, we
focus on modules and pathways demonstrating consistency across datasets and merge overlap-
ping modules subsequently. Thirdly, although we conducted validation experiments on the
CAV1 subnetwork in both in vitro and in vivo models and cross-validated the importance of the
predicted top key drivers and subnetworks in two independent large-scale mouse population
studies, further experiments are warranted to thoroughly test the causality of the predicted KDs
and elucidate the detailed tissue-specific mechanisms of the KDs on CVD and T2D. This is par-
ticularly important considering the limited overlaps in the modules and KDs identified from
our study and the ones identified in two recent multi-tissue network analysis of cardiometabolic
diseases [10, 11]. Only 7 KDs overlapped including APOA1,CD2,CEBPD,CENPF, CSF1R,
CTSS,UBE2S. Methodological differences in network inference and key driver analysis and dif-
ferences in the pathophysiological conditions of the study populations could explain the dis-
crepancies. Lastly, ethnic-specific and sex-specific mechanisms await future exploration.
There are several direct implications that can be drawn from the results of our integrative anal-
yses of both observational and experimental data. First, it appears that pathogenic pathways for
CVD and T2D are indeed common in ethnically diverse populations. These shared pathways cap-
ture most of the critical processes that have been previously implicated in the development of
either T2D or CVD, including metabolism of lipids and lipoproteins, glucose, fatty acids, bile
acids metabolism, biological oxidation, coagulation, immune response, cytokine signaling, and
PDGF signaling. Second, BCAA metabolism and ECM are among the top and common pathways
identified. Our finding on BCAA is consistent with recent work relating serum levels of BCAA to
risk of CVD and T2D in large prospective cohorts [42, 43], although whether BCAA is a “patho-
phenotype” or strong pathogenic factor has been debated [28, 44]. Our findings support a causal
role of BCAA because 1) both CVD and T2D risk variants were enriched in the co-expression
modules related to BCAA degradation, and 2) 15 genes in the BCAA pathway were part of the top
KD subnetworks, representing a significant enrichment of BCAA genes (fold enrichment = 3.02,
Fisher’s exact test p = 1.4e-5). Of note, BCAA genes themselves carry few genetic risk variants for
CVD and T2D, albeit their network neighboring genes are highly enriched for disease variants,
which may result from negative evolutionary pressure due to the critical role of BCAA. More
recently, Jang and colleagues have shown BCAA catabolism can cause insulin resistance, provid-
ing further support for the causal role of BCAA for both CVD and T2D [45]. Our finding on the
role of ECM in both CVD and T2D is also in line with recent reports [8, 13, 29, 30, 46]. In the top
enriched subnetworks, ECM genes appear to exert strong effect (Fig 4B) coordinating other pro-
cesses such as cholesterol metabolism, energy homeostasis, and immune response across a wide
range of peripheral tissues and endocrine axis. This substantiates the importance of ECM model-
ing as a mechanistic driver for CVD and T2D.
Secondly, our comprehensive network modeling identified critical disease modulators and
key targets whose functional roles were subsequently supported by multiple cross-validation
efforts. This supports the use of network modeling to unravel and prioritize promising top tar-
gets that may have high pathogenic potential for both CVD and T2D. The KDs we identified
can be considered as “highly confident” for the following reasons: 1) they are KDs for both
CVD and T2D associated modules, 2) the tissue-specific subnetworks of these KDs show sig-
nificant and replicable association with both diseases, 3) their subnetworks are highly enriched
with known CVD and T2D genes, 4) in vitro siRNA knockdown and in vivo knockout mouse
experiments confirm the role of a central KD CAV1 in regulating the downstream genes as
predicted in our network model, and 5) both the expression levels of KDs and the genetic vari-
ants mapped to the KD subnetworks are significantly associated with CVD and T2D relevant
traits in independent mouse populations with naturally occurring genetic variations.
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Thirdly, most KDs are not GWAS signals reaching genome-wide significance, nor are they
rare-variant carrying genes, indicating that standard genetic studies miss important genes that
orchestrate known CVD and T2D genes. The phenomenon may reflect a negative evolutionary
pressure experienced by the KDs due to their crucial functions. In support of this hypothesis,
we found a significant enrichment of human essential genes lacking functional variations
among the 162 KDs identified in our study [47] (Fold = 1.41, p = 9.02e-3). This is consistent
with previous findings [8, 9, 13] reaffirming the power and reliability of our approach in
uncovering hidden biological insights particularly in a systematic integrative manner.
The connections between KDs and other disease genes revealed by our study warrant future
investigation into the potential gene-gene interactions. Indeed, a closer examination of the bio-
logical functions from the top shared KDs further corroborates their disease relevance. For
instance, our network modeling identified HMGCR as a top KD, consistent with its primary
role as the target for cholesterol-lowering HMG-CoA inhibitors, namely statins. Our direc-
tionality inference analysis indicates that HMGCR is associated with CVD and T2D in opposite
directions. This is consistent with the recent findings that genetic variations in HMGCR that
decrease CVD risk cause slightly increased T2D risk, and statin drugs targeting HMGCR
reduces CVD risk but increases T2D risk [48–50]. CAV1 and IGF1 represent two tightly con-
nected multi-functional KDs. CAV1 null mice were found to have abnormal lipid levels, hyper-
glycemia, insulin resistance and atherosclerosis [33, 34]. Consistent with these observations,
we found strong association of CAV1 expression levels as well as CAV1 network with diverse
cardiometabolic traits in both human studies and mouse HMDP panels. Our data-driven
approach also revealed the central role of CAV1 in adipose tissue by elucidating its connection
to a large number of CVD and T2D GWAS genes and to genes involved in focal adhesion and
inflammation (Fig 4), which could drive adipocyte insulin resistance [51, 52]. The regulatory
effect of CAV1 on neighboring genes was subsequently validated using in vitro adipocyte and
in vivo mouse models. Moreover, our network modeling also captured the central role of
CAV1 in muscle and artery tissues, suggesting multi-tissue functions of CAV1 in the patho-
genic crossroads for CVD and T2D. The other multi-functional KD, IGF1, is itself a GWAS hit
for fasting insulin and HOMA-IR. Despite being primarily secreted in liver, in our study IGF1
demonstrated an adrenal gland and muscle specific regulatory circuit with CVD and T2D
genes, suggesting that it may confer risk to these diseases through the adrenal endocrine func-
tion and muscle insulin sensitivity. The three ECM KDs we identified, SPARC, PCOLCE and
COL6A2, were especially interesting due to their consistent and strong impact on diverse car-
diometabolic traits shown in our cross-validation analyses in HMDP (Fig 4, Fig 6). SPARC
encodes osteonectin, which is primarily circulated by adipocytes. It inhibits adipogenesis and
promotes adipose tissue fibrosis 50. SPARC is also associated with insulin resistance and coro-
nary artery lesions 51, 52. PCOLCE (procollagen C-endopeptidase enhancer) represents a novel
regulator for hypothalamus ECM that could potentially disrupt the neuroendocrine system.
COL6A2, on the other hand, provides new insights into how collagen may affect cardiometa-
bolic disorders: in adrenal tissue COL6A2 is connected to IGF1R, the direct downstream effec-
tor for KD IGF1. Importantly, our directionality analysis suggests that while some KDs such as
CAV1 may have similar directional effects on CVD and T2D, cases like HMGCR that show
opposite effects on these diseases are also present. Therefore, it is important to test the direc-
tional predictions to prioritize targets that have the potential to ameliorate both diseases and
deprioritize targets with opposite effects on the two diseases.
In summary, through integration and modeling of a multitude of genetics and genomics
datasets, we identified key molecular drivers, pathways, and gene subnetworks that are shared
in the pathogenesis of CVD and T2D. Our findings offer a systems-level understanding of
these highly clustered diseases and provide guidance on further basic mechanistic work and
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intervention studies. The shared key drivers and networks identified may serve as more effec-
tive therapeutic targets to help achieve systems-wide alleviation of pathogenic stress for cardio-
metabolic diseases, due to their central and systemic role in regulating scores of disease genes.
Such network-based approach represents a new avenue for therapeutic intervention targeting
common complex diseases.
Methods
Identification of qualified SNPs from GWAS of CVD and T2D
Detailed GWAS information including sample size, ethnicity and genotyping platform was
described in S4 Table and S1 Text. Briefly, p-values of qualified single nucleotide polymor-
phisms (SNPs) at minor allele frequency > 0.05 and imputation quality > 0.3 for CVD and
T2D were collected for all available GWAS datasets (WHI-SHARe, WHI-GARNET, JHS, FHS,
CARDIoGRAMplusC4D [19], and DIAGRAM [20]). SNPs meeting the following criteria were
further filtered out: 1) ranked in the bottom 50% (weaker association) based on disease associ-
ation p-values and 2) in strong linkage disequilibrium (LD) (r2> 0.5) according to ethnicity-
specific LD data from Hapmap V3 [53] and 1000 Genomes[54]. For each GWAS dataset, LD
filtering was conducted by first ranking SNPs based on the association p values and then
checking if the next highest ranked SNP was in LD with the top SNP. If the r2 was above 0.5,
the SNP with lower rank was removed. The step was repeated by always checking if the next
SNP was in LD with any of the already accepted ones.
Curation of data-driven gene co-expression network modules
Using the Weighted Gene Co-expression Network Analysis (WGCNA)[55], we constructed
gene co-expression modules capturing significant co-regulation patterns and functional relat-
edness among groups of genes in multiple CVD- or T2D-related tissues (including aortic
endothelial cells, adipose, blood, liver, heart, islet, kidney, muscle and brain) obtained from
nine human and mouse studies (S5 Table). Modules with size smaller than 10 genes were
excluded to avoid statistical artifacts, yielding 2,672 co-expression modules. These coexpres-
sion modules were used as a collection of data-driven sets of functionally connected genes for
downstream analysis. The potential biological functions of each module were annotated using
pathway databases Reactome and KEGG, and statistical significance was determined by Fish-
er’s exact test with Bonferroni-corrected p< 0.05.
Curation of functional genomics from eQTLs and ENCODE
eQTLs establish biologically meaningful connections between genetic variants and gene
expression, and could serve as functional evidence in support of the potential causal role of
candidate genes in pathogenic processes[56, 57]. We therefore conducted comprehensive
curation for significant eQTLs in a total of 19 tissues that have been identified by various con-
sortia (including the Genotype-Tissue Expression (GTEx) [58], Muther [59] and Cardiogenics
[60], and additional independent studies; S6 Table). Additional functional genomics resources
from ENCODE were also curated to complement the eQTLs for SNP-gene mapping (S1 Text).
Identification of genetically-driven CVD and T2D modules using Marker
Set Enrichment Analysis (MSEA)
MSEA was used to identify co-expression modules with over-representation of CVD- or T2D-
associated genetic signals for each disease GWAS in each cohort/ethnicity in a study specific
manner. MSEA takes into three input: 1) Summary-level results of individual GWAS (WHI,
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FHS, JHS, CARDIoGRAM+C4D, DIAGRAM) for the LD-filtered SNPs; 2) SNP-gene map-
ping information, which could be determined by tissue-specific cis-eQTLs, ENCODE based
functional annotation and chromosome distance based annotation. Cis-eQTLs is defined as
eQTLs within 1MB of the transcription starting sites of genes. For ENCODE, we accessed the
Regulome database and used the reported functional interactions to map SNPs to genes by
chromosomal distance. Only SNPs within 50kb of the gene region and have functional evi-
dence in Regulome database were kept; 3) Data-driven co-expression modules from multiple
human and mouse studies as described above. Tissue-specificity was determined by the tissue
origins of eQTLs and ethnic specificity was determined by the ethnicity of each GWAS cohort,
since the human disease genetic signals and human eQTL mapping were the main driving fac-
tors to determine the significance of the modules. MSEA employs a chi-square like statistic
with multiple quantile thresholds to assess whether a co-expression module shows enrichment
of functional disease SNPs compared to random chance [14]. The varying quantile thresholds
allows the statistic to be adoptable to studies of varying sample size and statistical power. For
the list of SNPs mapped to each gene-set, MSEA tested whether the SNP list exhibited signifi-
cant enrichment of SNPs with stronger association with disease using a chi-square like statistic:
w ¼
Pn
i¼1
Oi   Eiffiffiffi
Ei
p
þk
, where n denotes the number of quantile points (we used ten quantile points
ranging from the top 50% to the top 99.9% based on the rank of GWAS p values), O and E
denote the observed and expected counts of positive findings (i.e. signals above the quantile
point), and κ = 1 is a stability parameter to reduce artefacts from low expected counts for small
SNP sets. The null background was estimated by permuting gene labels to generate random
gene sets matching the gene number of each co-expression module, while preserving the
assignment of SNPs to genes, accounting for confounding factors such as gene size, LD block
size and SNPs per loci. For each co-expression module, 10000 permuted gene sets were gener-
ated and enrichment P-values were determined from a Gaussian distribution approximated
using the enrichment statistics from the 10000 permutations and the statistics of the co-expres-
sion module. Finally, Benjami-Hochberg FDR was estimated across all modules tested for each
GWAS.
To evaluate a module across multiple GWAS studies, we employed the Meta-MSEA analy-
sis in Mergeomics, which conducts module-level meta-analysis to retrieve robust signals across
studies. Meta-MSEA takes advantage of the parametric estimation of p-values in MSEA by
applying Stouffer’s Z score method to determine the meta-Z score, then converts it back to a
meta P-value. The meta-FDR was calculated using Benjamini-Hochberg method. Co-expres-
sion modules with meta-FDR < 5% were considered significant and included in subsequent
analyses.
Identification of key drivers and disease subnetworks
We used graphical gene-gene interaction networks including the GIANT networks [31] and
Bayesian networks (BN) from 25 CVD and T2D relevant tissue and cell types (S7 Table, S1
Text) to identify KDs. If more than one dataset was available for a given tissue, a network was
constructed for each dataset and all networks for the same tissue were combined as a union to
represent the network of that tissue, with the consistency of each network edge across datasets
coded as edge weight. The co-expression modules genetically associated with CVD or T2D
identified by Meta-MSEA were mapped onto these graphical networks to identify KDs using
the weighted key driver analysis (wKDA) implemented in Mergeomics [14]. wKDA uniquely
consider the edge weight information, either in the form of edge consistency score in the case
of BNs or edge confidence score in the case of GIANT networks. Specifically, a network was
first screened for suitable hub genes whose degree (number of genes connected to the hub) is
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in the top 25% of all network nodes. Once the hubs have been defined, their local one-edge
neighborhoods, or “subnetworks” were extracted. All genes in each of the CVD and T2D-asso-
ciated gene sets that were discovered by meta-MSEA were overlaid onto the hub subnetworks
to see if a particular subnetwork was enriched for the genes in CVD/T2D associated gene sets.
The edges that connect a hub to its neighbors are simplified into node strengths
(strength = sum of adjacent edge weights) within the neighborhood, except for the hub itself.
The test statistic for the wKDA is analogous to the one used for MSEA: w ¼ O  EffiffiE
p
  k
, except that
the values O and E represent the observed and expected ratios of genes from CVD/T2D gene
sets in a hub subnetwork. In particular, E ¼ NkNpN is estimated based on the hub degree Nk, dis-
ease gene set size Np and the order of the full network N, with the implicit assumption that the
weight distribution is isotropic across the network. Statistical significance of the disease-
enriched hubs, henceforth KDs, is estimated by permuting the gene labels in the network for
10000 times and estimating the P-value based on the null distribution. To control for multiple
testing, stringent Bonferroni adjustment was used to focus on the top robust KDs. KDs shared
by CVD and T2D modules are prioritized based on the following criteria: i) Bonferroni-cor-
rected p< 0.05 in wKDA, ii) replicated by both GIANT networks and Bayesian networks, and
iii) the genetic association strength between the KD subnetworks (immediate network neigh-
bors of the KDs) and CVD/T2D in Meta-MSEA. Finally, Cytoscape 3.3.0 [61] was used for dis-
ease subnetwork visualization.
Inference of the direction of genetic effects of KD subnetworks
We used the genetic effect direction of KDs as a proxy for probable effect direction of the KD
subnetworks. For each KD, we retrieved their tissue-specific eQTLs as well as variants within
50kb of the gene region, whose genetic association information was available in both CARDIo-
GRAMplusC4D and DIAGRAM, the two large meta-consortia of GWAS for CVD and T2D.
CVD/T2D association beta-values of mapped variants of KDs were then extracted, and the
signs of beta-values were examined to ensure they were based on the same reference alleles
between GWAS. Lastly, for all mapped variants on each KD, the signs of the beta-value for
CVD and T2D were compared and statistical significance of the proportion of variants with
similar or opposite effect direction between diseases was determined by z-test.
Validation of KD subnetwork topology using siRNA knockdown in
adipocytes
We chose to validate the predicted adipose subnetwork of a top ranked KD of both CVD and
T2D, Cav1, in 3T3-L1 adipocytes. Cells were cultured to confluence and adipocyte differentia-
tion was induced using MDI differentiation medium (S1 Text). Two days after the initiation
of differentiation, cells were transfected with 50 nM Cav1 siRNAs (3 distinct siRNAs were
tested and two of the strongest ones were chosen) or a scrambled control siRNA. For each
siRNA, two separate sets of transfection experiments were conducted, with three biological
replicates in each experiment. Two days after transfection, cells were collected for total RNA
extraction, reverse transcription and quantitative PCR measurement of 12 predicted Cav1 sub-
network genes and 5 random genes not within the subnetwork as negative controls (S1 Text).
β-actin was used to normalize the expression level of target genes.
Validation of KD subnetwork topology using Cav1 null mice
We accessed the gonadal white tissue gene expression data of 3-month-old wild type and
Cav1-/- male mice (N = 3/group) from Gene Expression Omnibus (GEO accession:
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GSE35431). Detailed description of the data collection procedures has been described previ-
ously [33]. Gene expression was profiled using Illumina MouseWG-6 v2.0 expression beadchip
and normalized using robust spline. Differentially expressed genes (DEGs) between genotype
groups were identified using linear model implemented in the R package Limma and false dis-
covery rate was estimated using the Benjamini-Hochberg procedure [62]. DEGs at different
statistical cutoffs were compared to CAV1 subnetwork genes at different levels (i.e., 1, 2, 3, or 4
edges away from CAV1) to assess overlap and significance of overlap was evaluated using Fish-
er’s exact test.
Validation of KD subnetworks using mouse HMDP studies
To further validate the role of KD subnetworks in CVD and T2D, we incorporated genetic,
genomic and transcriptomic data from HMDP (comprised of>100 mouse strains differing by
genetic composition) [21–23]. HMDP data was from two panels, one with mice fed with a
high-fat diet (HF-HMDP)[22], and the other with hyperlipidemic mice made by transgenic
expression of human APOE-Leiden and CETP gene (ATH-HMDP)[23]. For HF-HMDP, we
retrieved gene-trait correlation data for adipose tissue (due to its relevance to both CVD and
T2D) and 7 core cardiometabolic traits including adiposity, fasting glucose level, fasting insu-
lin level, LDL, HDL, triglycerides and homeostatic model assessment-insulin resistance
(HOMA-IR). For ATH-HMDP, we retrieved aorta gene-trait correlation (aorta tissue is the
main site for CVD in mice) for all 7 traits. In addition to assessing the trait association
strengths of individual KDs, we also used MSEA to evaluate the aggregate association strength
of the top CVD/T2D KD subnetworks with the traits at both transcription and genetic levels
through transcriptome-wide association (TWAS) and GWAS in HF-HMDP and ATH-HMDP
(S1 Text).
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